Joseph Ludwig
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joseph Ludwig as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:54 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07781891 · RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCTM.D. Anderson Cancer Center · not yet recruiting · Ewing Sarcoma · principal investigator
- N/ANCT04199026 · Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaM.D. Anderson Cancer Center · recruiting · Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- RAPID: A patient-centric, investigator-initiated, Bayesian-designed, open-label, phase 2 platform trial of promising drugs for AYA patients with relapsed/refractory Ewing sarcoma & DSRCT.R01FD008794 · FDA · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2026 · $899,917 awarded in 2026Same name and institution; not confirmed by an ID
- 3D Model of Human Ewing SarcomaR01CA180279 · NCI · RICE UNIVERSITY · fiscal years 2014 to 2018 · $221,019 awarded in 2018Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name in ewing sarcoma, ranked by citations from NIH iCite, fetched 2026-11-12 09:54 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.Clin Cancer Res · 2012167 citationsRCR 4.4
- Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.J Clin Oncol · 202438 citationsRCR 4.6